FivepHusion

Investor Presentation
BioShares 2026 - Update

NEXT-GENERATION CANCER THERAPEUTICS

ADDRESSING CLINICIAN NEEDS, FOR THEIR PATIENTS

Dr Christian Toouli, CEO & Managing Director
c.toouli@fivephusion.com

Next-Generation Standard of Care (SOC)

Optimising 5-Fluorouracil (5-FU) clinical activity to generate superior treatment outcomes

5-FU (in various combinations)	• **A standard of care (SOC) for cancers with >8m patient incidence** • Colorectal (CRC), pancreatic, head & neck, gastric, breast etc.…
SOC but Sub-Optimal	• **Limited efficacy due to chemical incompatibility of its biomodulator leucovorin (LV)** • New drugs are typically added onto this sub-optimal backbone therapy
Clinical Opportunity	• **Optimise 5-FU to increase safety & efficacy for existing indications** • **Exploit advantages to repurpose for strategic opportunities**
GLOBAL BLOCKBUSTER MARKET	• **Next generation backbone therapy for existing and new cancers**

STRATEGY: (1) Exploit fast-to-market repurposing for paediatric ependymoma

(2) Leverage into larger metastatic colorectal cancer backbone therapy opportunity

DEFLEXIFOL®: FIRST-IN-CLASS & BEST-IN-CLASS TREATMENT

FivepHusion

A novel & optimised therapy

- Superior co-formulation of **5-fluorouracil (5-FU)** & its biomodulator **leucovorin (LV)**
- **Maximised synergy achieving greater safety & potency**

Broad therapeutic utility & market opportunities

- Priorities:
  - **paediatric ependymoma (brain) cancer (FIRST-IN-CLASS)**
  - **1st line metastatic colorectal cancer (BEST-IN-CLASS)**
- **Significant upside** potential in 5-FU treated tumours
  - pancreatic, gastric, head & neck & breast (BEST-IN-CLASS)

Clinically advanced, technically & commercially low risk

- 3 phase I clinical studies successfully completed (Total N = 68)
  - **Greater safety, tolerability & efficacy**
- 5x independent surrogate phase II trials
  - **Greater response rate and survival in mCRC**
- Fast-tracked, low-risk 505(b)(2) regulatory pathway
- Low-cost, scalable manufacture with Pfizer
- **Peak sales estimate $1.8B (conservative priority + upside)**
- Composition of matter IP + patent pipeline exclusivity to 2046

Update

pII ependymoma trial launch (Aug 2026)

REPURPOSING FOR PAEDIATRIC EPENDYMOMA

A leading drug candidate for a significant unmet medical need

PAEDIATRIC EPENDYMOMA	• **The third most common brain cancer in children** • 4 per million incidence; peak <4 years of age
CURRENT TREATMENT	• **No approved drug therapies** • Surgical resection and adjuvant radiotherapy
5-FU RATIONALE	• **Off-label compassionate use** • **Sensitisation via frequent chromosome 1q+**

(PRECEDENT) ST JUDE 5-FU PHASE I TRIAL[1]	• **A 48% disease control rate** (5/23 PR and 6/23 SD)
	  • Maximum *tolerated* dose: **400 mg/m² bolus dose**
	  • Minimum *effective* dose: **500 mg/m² bolus dose**

[1] Wright et al. 2015, *Neuro Oncol.*, 17(12):1620-27

5-FU ACTIVITY BUT NO SAFE THERAPEUTIC DOSE

Promising mechanism, growing pre-clinical & clinical data set, but limited utility in current formulations

PAEDIATRIC EPENDYMOMA	• **The third most common brain cancer in children** • 4 per million incidence; peak <4 years of age
CURRENT TREATMENT	• **No approved drug therapies** • Surgical resection and adjuvant radiotherapy
5-FU RATIONALE	• **Off-label compassionate use** • **Sensitisation via frequent chromosome 1q+**
(PRECEDENT) ST JUDE 5-FU PHASE I TRIAL[1]	• **A 48% disease control rate** (5/23 PR and 6/23 SD) • Maximum *tolerated* dose: **400 mg/m² bolus dose** • Minimum *effective* dose: **500 mg/m² bolus dose**



[1] Wright et al. 2015, *Neuro Oncol.*, 17(12):1620-27

DEFLEXIFOL®: FIRST FOR PAEDIATRIC EPENDYMOMA

Exploiting greater potency & improved safety & tolerability

Phase I/II Deflexifol® at Relapse Trial (DART)

Phase I: Various brain cancers - SUCCESSFULLY COMPLETED

- N = 9: ependymoma (n=6), DMG (n=2) and ETMR (n=1)
- MTD - 525mg/m^2 bolus + 3000mg/m^2 infusion
  - **Deflexifol® : ~9x St Jude phase 1 MTD**

* ACTRN12623000104651 (link); #SNO 2025 poster (link); DMG = Diffuse Midline Glioma; ETMR = Embryonal Tumor with Multilayered Rosettes; HREC = Human Research Ethics Committee

DEFLEXIFOL®: FIRST FOR PAEDIATRIC EPENDYMOMA

Exploiting greater potency & improved safety & tolerability

Phase I/II Deflexifol® at Relapse Trial (DART)

Phase I: Various brain cancers - SUCCESSFULLY COMPLETED

- N = 9: ependymoma (n=6), DMG (n=2) and ETMR (n=1)
- MTD - 525mg/m² bolus + 3000mg/m² infusion
    - **Deflexifol® : ~9x St Jude phase 1 MTD**

Phase II: Recurrent or refractory ependymoma

- N = 10, 7 evaluable patients to be recruited (3 evaluable from Phase I)
- Response, survival and safety endpoints
- Eight clinical sites around Australia
- **Estimated top-line data H2 2027**

Investigating Deflexifol® at an expected safe, tolerable & efficacious dose



* ACTRN12623000104651 (link); #SNO 2025 poster (link); DMG = Diffuse Midline Glioma; ETMR = Embryonal Tumor with Multilayered Rosettes; HREC = Human Research Ethics Committee

Value Creation Strategy – Accelerate to Pivotal Trial

FivepHusion

Value Catalysts	2026	2027	2028	2029+
mCRC (Best-In-Class)	FDA TYPE C; Phase 1 x2	Manufacturing Scale-Up	Phase Ib/IIa dose confirmation	Phase III Registration trial; Market Launch
Paediatric Ependymoma (First-in-class)	DART Phase I	DART Phase II	Pivotal trial	Market Launch
Other 5-FU treated cancers				Phase Ib/II trials (other 5-FU treated cancers)

Licensing, partnering deals &/or acquisition

Recent Paediatric Brain Cancer Deal Precedents

Date	Type of Deal	Acquirer/Licensee	Target/Licensee	Stage	Upfront (US$)	Milestones (US$)	Total Deal Value (US$)
Mar-25	Acquisition	Jazz Pharmaceuticals	CHIMERIX	Phase 3	$935m	-	**$935m**
Jul-24	Licensing Agreement	IPSEN	Day One Biopharmaceuticals	Phase 3	$111m	$350m	**$461m**
Mar-26	Acquisition	SERVIER	Day One Biopharmaceuticals	Commercial	$2,500m		**$2,500m**

All development steps and timelines are indicative; IND = FDA Investigational New Drug Application

Experienced Leadership & Strategic Partners

Established highly experienced Board, Management and Advisory Teams

Board

David Ranson
Executive Chairman
BEng(ElecEng)

Dr. Christian Toouli
CEO & Managing Director
Btech Hons; PhD; GAICD

Dr. Bill Ketelbey
Executive Director
MBBCh; FFPM; MBA; GAICD

Iain Ross
Non-Executive Director
BSc Hons; CDir (IoD)

Strategic Collaborations

Independent Clinical Advisory Board

Advising on the clinical strategy and trial design for Deflexifol® registration for use in adult cancers

Prof. Stephen Clarke OAM
Chairman

Prof. John Simes AO

Prof. Andrew McLachlan AM

Prof. John Zalcberg AO

Founder Advisory Board

Inventors of Deflexifol® contributing expertise to ongoing development

Prof. Philip Clingan OAM

Senior Prof. Marie Ranson

Emeritus Prof. John Bremner AM

FIVEPHUSION KEY HIGHLIGHTS

FivepHusion

FivepHusion's strategy presents a unique and compelling risk-reward profile

Multiple Blockbuster Markets	• **Paediatric ependymoma – Part of the US$1.32B paediatric brain cancer market -** rapid path to additional indications • **Metastatic colorectal cancer (mCRC)** ≤570k patient incidence = **US$13B mCRC market** • **8.0m+ solid tumour diagnosed p.a**. (where 5-FU + LV are utilised)
Deflexifol® First-In-Class & Best-In-Class	• **Aiming to be the first approved therapy for paediatric ependymoma** • 5-FU + LV: Established standard of care' backbone therapy for mCRC (95% of patients). • **Aims to replace current 'standard of care' (SOC) backbone therapy**
Strong economics	• **Premium pricing** potential vs. generics, **driven by superior safety and efficacy** • **Rapid uptake** - KOLs believe **Deflexifol®** would be **widely adopted within 2 years** of clinical validation and launch • Conservative Modelling suggests **peak sales ~$1.8B+** (multiplies on higher pricing)
Clinically Validated	• 3x company clinical trials demonstrated **higher safety & tolerability** and **potent efficacy** • Current clinician 5-FU off-label use to treat ependymoma • 5x independent surrogate Phase II trials confirm rationale and therapeutic mechanism
Fast-tracked & Capital-Efficient	• Paediatric ependymoma – fast-tracked orphan indication; exploiting poor therapeutic window for 5-FU • **Active Phase II paediatric ependymoma** trial moving towards a pivotal trial • Fast-tracked development via 505(b)(2) pathway for 5-FU-treated cancers **enabling faster, lower cost approval** • Rare in oncology: **Deflexifol® is a 'next generation' superior co-formulation** (with composition of matter patents),
Significant Pipeline	• **Broader applications where 5-FU + LV are utilised**: pancreatic, gastric, breast, head & neck cancers
IP Protection	• **Granted Composition of Matter patents and pipeline**, expected **exclusivity to 2046**
Licensing Transactions	• Clear, short-term pathway to **regional and global licensing transaction opportunities with lucrative deal precedents**

Millions of cancer patients are treated with chemotherapy unchanged since last century

FivepHusion is optimising treatment safety and efficacy, & unlocking multi-billion-dollar commercial opportunities

Contact: Dr Christian Toouli, CEO & Managing Director
c.toouli@fivephusion.com

DISCLAIMER

By accepting this presentation or attending a presentation (whether in person or by video conference), the recipient (**you**) agrees to be bound by the following terms and conditions. The purpose of this presentation is to provide general information about Detsamma Investments Pty Ltd (ABN:85 630 579 547) (trading as **"FivepHusion"**) and its business.

This presentation does not constitute an offer, invitation or recommendation to subscribe for, or purchase, any security or financial product or an advertisement for the same. This document is not a prospectus, disclosure document, product disclosure statement or other offer or disclosure document under Australian law or the laws of any other jurisdiction. This presentation does not constitute the provision of financial product or investment advice. You should seek independent legal, financial, regulatory and taxation advice before making any decision in respect of this presentation. You represent and warrant that you fall within one or more of the categories of "sophisticated" or "professional" investors as described in sections 708(8) and 708(11) of the Corporations Act 2001 (Cth), or that you are otherwise a person to whom this presentation may be provided under the securities laws of any applicable jurisdiction.

FivepHusion and its officers, employees, consultants and advisors do not make any guarantee, representation or warranty, either expressed or implied concerning the accuracy, completeness or reliability of the information contained in this presentation or accept any responsibility for errors or omissions in any information contained in this presentation or the future performance of FivepHusion; and disclaim and exclude all liability for the accuracy, completeness or reliability of the information contained in this presentation (or any error or omission thereof), and exclude all liability whatsoever for any loss, damage or costs (whether foreseeable or not and whether direct, indirect or consequential) which may be suffered by any person as a consequence of any information in this presentation or any error in or omission from it, whether the loss or damage arises in tort (including negligence), contract, statute or otherwise. Specifically, FivepHusion does not warrant or represent that the information contained in this presentation has been audited, except where specifically stated otherwise.

This presentation may include forward-looking statements, which reflect various assumptions that may or may not prove to be correct. Actual results may be materially affected by known and unknown risks including changes in economic conditions and other circumstances which may be outside the control of FivepHusion. The reliance that recipients place upon such information is a matter for their own commercial judgement however you are cautioned not to place undue reliance on forward-looking statements and to seek professional advice if in doubt.

All warranties, conditions, liabilities or representations in relation to information or advice contained in this presentation are expressly negated and excluded to the maximum extent permitted by law. The recipient agrees, to the fullest extent permitted by law that he/she shall not seek to sue or hold FivepHusion or its officers, employees, consultants and advisors liable in any respect by reason of provision of this presentation.

This information in this presentation is being furnished to you solely for your information and may not be reproduced, in whole or in part, or distributed to any other person, without the consent of FivepHusion.